Report Detail
Reflux Esophagitis - Pipeline Review, H2 2019
- RnM3784272 |
- 26 September, 2019 |
- Global |
- 98 Pages |
- Global Markets Direct |
- Pharma & Healthcare
Reflux Esophagitis - Pipeline Review, H2 2019
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Reflux Esophagitis - Pipeline Review, H2 2019, provides an overview of the Reflux Esophagitis (Gastrointestinal) pipeline landscape.
When the liquid content of the stomach refluxes into the esophagus, that condition is called Gastroesophageal reflux disease (GERD). It is a chronic condition. The symptoms of GERD are nausea, heartburn and vomiting. The predisposing factors include eating large meals, which can cause the Lower Esophageal Sphincter (LES) to open inappropriately, as well as obesity, pregnancy, greasy food and certain drugs.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Reflux Esophagitis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Reflux Esophagitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Reflux Esophagitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Reflux Esophagitis (Gastroesophageal Reflux Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 7, 7, 7, 4, 1 and 1 respectively.
Reflux Esophagitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Reflux Esophagitis (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Reflux Esophagitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Reflux Esophagitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Reflux Esophagitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Reflux Esophagitis (Gastrointestinal)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Reflux Esophagitis (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Reflux Esophagitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Overview
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Companies Involved in Therapeutics Development
Ahn-Gook Pharmaceutical Co Ltd
Chong Kun Dang Pharmaceutical Corp
CJ HealthCare Corp
Daewoong Pharmaceutical Co Ltd
Eisai Co Ltd
Handa Pharmaceuticals LLC
Ilyang Pharmaceutical Co Ltd
Ironwood Pharmaceuticals Inc
Jeil Pharmaceutical Co Ltd
RaQualia Pharma Inc
Sam-A Pharm Co Ltd
Sun Pharma Advanced Research Company Ltd
Takeda Pharmaceutical Co Ltd
XuanZhu Pharma Co Ltd
Yooyoung Pharm Co Ltd
Yuyu Pharma Inc
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Drug Profiles
(esomeprazole + sodium bicarbonate) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
azeloprazole sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ceclazepide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CG-20043 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CJ-30065 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
colesevelam - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dexlansoprazole DR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DWP-14012 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
esomeprazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
G-17DT - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HND-009 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ilaprazole DR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IYHCR-17 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JP-1366 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KBP-3571 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naronapride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
netazepide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pantoprazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pantoprazole DR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pantoprazole sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RQ-00000774 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SA-15001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tegoprazan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vonoprazan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
X-842 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XY-066 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YY-DXR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Dormant Projects
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Discontinued Products
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Product Development Milestones
Featured News & Press Releases
Aug 28, 2019: Sales of new gastric acid blocker K-Cab top 10 billion
May 09, 2019: Ironwood Pharmaceuticals to highlight IW-3718 data at Digestive Disease Week 2019
Apr 25, 2019: Sihuan Pharm's innovative digestive system drug Anaprazole Sodium achieved early completion of patient recruitment for phase II clinical trial in China
Mar 27, 2019: CJ Healthcare releases P3 trial results for gastroesophageal reflux treatment
Oct 08, 2018: Ironwood Pharmaceuticals presents IW-3718 data at the American College of Gastroenterology 2018 Annual Scientific Meeting
Jul 06, 2018: Ministry approves CJ Healthcares gastroesophageal reflux treatment
Jul 06, 2018: RaQualia Announces Receipt of Milestone Payment from CJ HealthCare
Jun 21, 2018: Ironwood begins two Phase III trials of IW-3718
Jun 05, 2018: Ironwood Pharmaceuticals Presents IW-3718 Data Showing Improvements in Heartburn and Regurgitation Symptoms in Patients with Persistent GERD at Digestive Disease Week 2018
Jun 05, 2018: Ironwood Pharmaceuticals Presents IW-3718 Data Showing Improvements in Heartburn and Regurgitation Symptoms in Patients with Persistent GERD at Digestive Disease Week 2018
May 23, 2018: Ironwood Pharmaceuticals to Highlight Clinical Data for IW-3718 in Persistent Gastroesophageal Reflux Disease (GERD) at Digestive Disease Week 2018
Apr 16, 2018: First clinical study successfully completed with X842, an innovative promising treatment for severe erosive GERD
Jul 20, 2017: Ironwood Pharmaceuticals Reports Positive Top-line Results from IW-3718 Phase IIb Trial in Uncontrolled Gastroesophageal Reflux Disease
Mar 09, 2017: Ironwood Pharmaceuticals provides update on key pipeline program IW-3718 at R&D Day 2017
Nov 16, 2016: Renexxion Achieves Positive FDA Guidance for Phase 3-ready GI Drug Naronapride
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Summary:
Get latest Market Research Reports on Reflux Esophagitis. Industry analysis & Market Report on Reflux Esophagitis is a syndicated market report, published as Reflux Esophagitis - Pipeline Review, H2 2019. It is complete Research Study and Industry Analysis of Reflux Esophagitis market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
